WHAT THE PARALLEL IMPORT IS
The parallel import or parallel trade for medicines is a lawful form of trade between EU Member States based on Articles 28 and 30 of the EC Treaty.
A parallel imported medicine is subject to a parallel import license (AIP) granted by the Italian Medicines Agency ( AIFA) quite similar to a marketing authorization AIC, and it is identified by a unique ID number of the product, dosage and pharmaceutical pack, Country of Origin, marketing holder. This number AIP is written on an optical label, printed by the "Poligrafico dello Stato".
After obtaining the import authorization by AIFA, the importer can buy the drug in the Origin Country (always within the European Economic Area) and it has to make it suitable to be marketed in Italy through a repackaging in accordance with national regulations and in order to make fit the language and contents to existing homologue ones.
The medicine imported is so absolutely exactly alike to the one already marketed in the country of destination, in qualitative and quantitative composition of active ingredients, in dosage, in indications, and in side effects. The quality is guaranteed by the producer and brand holder that are the same in the different European countries.
Gekofar currently holds around 80 parallel import authorizations for medicinal products of different classes (class A, C, OTC and SOP).
The complete list of Gekofar medicines is on the page «PRODUCTS»